The Food and Drug Administration approved a new migraine drug on Thursday the drug known generically as erenumab, is the first drug in a new class of headache medicines. It's been shown to stop migraine headaches before they start. The drug would be approved for patients who have tried other drugs and found no relief. In studies, it did not entirely prevent migraines but reduced their frequency. "Erenumab provides patients with a novel option for reducing the number of days with a migraine,” said, deputy director of the FDA's neurology products division.“We need new treatments for this painful and often debilitating condition.”FDA's approval means the drug may soon be available under prescription.
It should also be paid for by health insurance. The drug's maker said U.S. list price is for the once monthly self-injection treatment will be $575 per month or $6,900 annually. Erenumab the…
